A Study to Evaluate the Efficacy/Safety of Transdermal Testosterone for 52 Weeks and Safety for 52 Weeks in Naturally Menopausal Women With Hypoactive Sexual Desire Disorder on Oral Hormone Replacement Therapy.
Phase of Trial: Phase III
Latest Information Update: 30 Mar 2010
At a glance
- Drugs Testosterone (Primary)
- Indications Decreased libido
- Focus Therapeutic Use
- Sponsors Procter & Gamble
- 30 Mar 2010 Warner Chilcott added as trial sponsor and trial affiliate as reported by ClinicalTrials.gov.
- 20 Oct 2009 Additional lead trial investigator identified as reported by ClinicalTrials.gov.
- 14 Feb 2008 The expected completion date for this trial is now 1 Jul 2006.